St. Teresa was founded in 2010 to commercialize an innovative technology developed at Virginia Commonwealth University (VCU) in collaboration with the Henry Jackson Foundation for the Advancement of Military Medicine. St Teresa has produced the next generation of disruptive products by combining medicinals in a medical device to reduce uncontrolled bleeding. The unique solution to fibrin sealant hemostasis is its CONTACT NANO-LIGATION™ soft matter technology, SurgiClot. We are focused on treating surgical bleeding.